New drug enters first human tests for rheumatoid arthritis
NCT ID NCT07052032
Summary
This early-stage study is testing the safety and side effects of an experimental drug called CND261 in adults with active rheumatoid arthritis. The trial will enroll 47 participants who haven't responded well to current treatments to see how their bodies handle the medication. Researchers will monitor patients for a full year to gather initial safety data and understand how the drug behaves in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Candid Clinical Site
RECRUITINGTbilisi, Georgia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Candid Clinical Site
RECRUITINGChisinau, Moldova
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Candid Clinical Site
RECRUITINGAuckland, New Zealand
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Candid Clinical Site
RECRUITINGBucharest, Romania
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Candid Clinical Site
RECRUITINGCluj-Napoca, Romania
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Candid Clinical Site
RECRUITINGKyiv, Ukraine
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.